CT-based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castration-naïve oligometastatic prostate cancer.

Prostate · 2021 · PMC7839584 · PMID 33259087

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

Aggressive neoadjuvant therapy and prostatectomy in patients with metastatic disease represent a promising approach, 13 but there may be significant consequences to the overall well‐being of the patients and quality of life, as borne out by the observed changes in body composition.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.